Topics:

Juvenile Arthritis

Best of EULAR 2014

What you missed by not going to Paris this year, other than great wine and fresh croissants: Sex (and gout). Smoking (bacteria, and RA). Pain relief (and its importance to the success of RA medication). A virus (papilloma, and JIA). And yet more ...

Juvenile Arthritis

A new international multicenter study of often-deadly macrophage activation syndrome in systemic JIA reveals key laboratory and clinical warning signs. Watch ferritin levels especially closely.

A new auto-injectable form of methotrexate offers 10 dosage options. Is this an important advantage for medication management and adherence over the four already available?

Three proposed standardized treatment plans may also aid research into managing newly-diagnosed polyarticular juvenile idiopathic arthritis.

(EULAR 2014) Analysis of 7-month results show few problems and great benefit for the Gardasil vaccine against human papilloma virus in girls or young women with juvenile arthritis.

(ACR Pediatrics 2014) Children growing into young adults with rheumatic diseases often fail to get the care they need, for numerous complicated reasons. The ACA could change all this, with implications for adult rheumatologists. Here, a brief look at the situation and some solutions.

(ACR Pediatrics 2014) Large research partnerships are proving key to conquering childhood rheumatic diseases like juvenile idiopathic arthritis. To continue the advance, however, larger mergers and newer kinds of data are required.

(ACR Pediatrics 2014) New biologics have revolutionized care for children with juvenile arthritis in recent years. But a pediatric rheumatologist says this progress isn't nearly good enough, urging a much tougher agenda.

Pages

Subscribe to Juvenile Arthritis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.